|
1
|
Suh Y, Amelio I, Urbano T Guerrero and
Tavassoli M: Clinical update on cancer: Molecular oncology of head
and neck cancer. Cell Death Dis. 5:e10182014. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thomas SM and Grandis JR: The current
state of head and neck cancer gene therapy. Hum Gene Ther.
20:1565–1575. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Maiti GP, Mondal P, Mukherjee N, Ghosh A,
Ghosh S, Dey S, Chakrabarty J, Roy A, Biswas J, Roychoudhury S and
Panda CK: Overexpression of EGFR in head and neck squamous cell
carcinoma is associated with inactivation of SH3GL2 and CDC25A
genes. PLoS One. 8:e634402013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Martinez-Useros J and Garcia-Foncillas J:
The challenge of blocking a wider family members of EGFR against
head and neck squamous cell carcinomas. Oral Oncol. 51:423–430.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Ahn SH, Choi JY, Kim DW, Lee DY, Jeon EH,
Jeong WJ and Paik JH: Targeting HIF1α peri-operatively increased
post-surgery survival in a tongue cancer animal model. Ann Surg
Oncol. 22:3041–3048. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Liang J, Zhang Z, Liang L, Shen Y and
Ouyang K: HIF-1α regulated tongue squamous cell carcinoma cell
growth via regulating VEGF expression in a xenograft model. Ann
Transl Med. 2:922014.PubMed/NCBI
|
|
7
|
Hamilton AJ and Baulcombe D: A species of
small antisense RNA in posttranscriptional gene silencing in
plants. Science. 286:950–952. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Napoli C, Lemieux C and Jorgensen R:
Introduction of a chimeric chalcone synthase gene into petunia
results in reversible co-suppression of homologous genes in trans.
Plant Cell. 2:279–289. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fire A, Xu S, Montgomery MK, Kostas SA,
Driver SE and Mello CC: Potent and specific genetic interference by
double-stranded RNA in Caenorhabditis elegans. Nature. 391:806–811.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Collins RE and Cheng X: Structural and
biochemical advances in mammalian RNAi. J Cell Biochem.
99:1251–1266. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Agrawal N, Dasaradhi PVN, Mohmmed A,
Malhotra P, Bhatnagar RK and Mukherjee SK: RNA interference:
Biology, mechanism, and applications. Microbiol Mol Biol Rev.
67:657–685. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J,
Lee J, Provost P, Rådmark O, Kim S and Kim VN: The nuclear RNase
III drosha initiates microRNA processing. Nature. 425:415–419.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wilson RC and Doudna JA: Molecular
mechanisms of RNA interference. Annu Rev Biophys. 42:217–239. 2003.
View Article : Google Scholar
|
|
14
|
Filipowicz W, Jaskiewicz L, Kolb FA and
Pillai RS: Post-transcriptional gene silencing by siRNAs and
miRNAs. Curr Opin Struct Biol. 15:331–341. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Liu Q and Paroo Z: Biochemical principles
of small RNA pathways. Annu Rev Biochem. 79:295–319. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ouellet DL, Perron MP, Gobeil LA, Plante P
and Provost P: MicroRNAs in gene regulation: When the smallest
governs it all. J Biomed Biotechnol. 2006:696162006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Yeom KH, Lee Y, Han J, Suh MR and Kim VN:
Characterization of DGCR8/Pasha, the essential cofactor for Drosha
in primary miRNA processing. Nucleic Acids Res. 34:4622–4629. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Khvorova A, Reynolds A and Jayasena SD:
Functional siRNAs and miRNAs exhibit strand bias. Cell.
115:209–216. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Schwarz DS, Hutvágner G, Du T, Xu Z,
Aronin N and Zamore PD: Asymmetry in the assembly of the RNAi
enzyme complex. Cell. 115:199–208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Meister G, Landthaler M, Patkaniowska A,
Dorsett Y, Teng G and Tuschl T: Human Argonaute2 mediates RNA
cleavage targeted by miRNAs and siRNAs. Mol Cell. 15:185–197. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Elbashir SM, Martinez J, Patkaniowska A,
Lendeckel W and Tuschl T: Functional anatomy of siRNAs for
mediating efficient RNAi in Drosophila melanogaster embryo lysate.
EMBO J. 20:6877–6888. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Eulalio A, Huntzinger E and Izaurralde E:
Getting to the root of miRNA-mediated gene silencing. Cell.
132:9–14. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Gregory RI, Chendrimada TP, Cooch N and
Shiekhattar R: Human RISC couples microRNA biogenesis and
posttranscriptional gene silencing. Cell. 123:631–640. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Meister G: miRNAs get an early start on
translational silencing. Cell. 131:25–28. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Pecot CV, Calin GA, Coleman RL,
Lopez-Berestein G and Sood AK: RNA interference in the clinic:
Challenges and future directions. Nat Rev Cancer. 11:59–67. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bouard D, Alazard-Dany D and Cosset FL:
Viral vectors: From virology to transgene expression. Br J
Pharmacol. 157:153–165. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kantor B, Bailey RM, Wimberly K, Kalburgi
SN and Gray SJ: Methods for gene transfer to the central nervous
system. Adv Genet. 87:125–197. 2014.PubMed/NCBI
|
|
28
|
Galanis E, Vile R and Russell SJ: Delivery
systems intended for in vivo gene therapy of cancer: Targeting and
replication competent viral vectors. Crit Rev Oncol Hemato.
38:177–192. 2001. View Article : Google Scholar
|
|
29
|
Morris KV and Rossi JJ:
Lentiviral-mediated delivery of siRNAs for antiviral therapy. Gene
Ther. 13:553–558. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wold WS and Toth K: Adenovirus vectors for
gene therapy, vaccination and cancer gene therapy. Curr Gene Ther.
13:421–433. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hermens WT and Verhaagen J: Viral vectors,
tools for gene transfer in the nervous system. Prog Neurobiol.
55:399–432. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Tomar RS, Matta H and Chaudhary PM: Use of
adeno-associated viral vector for delivery of small interfering
RNA. Oncogene. 22:5712–5715. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Lentz TB, Gray SJ and Samulski RJ: Viral
vectors for gene delivery to the central nervous system. Neurobiol
Dis. 48:179–188. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ramamoorth M and Narvekar A: Non viral
vectors in gene therapy-an overview. J Clin Diagn Res. 9:GE01–GE06.
2015.PubMed/NCBI
|
|
35
|
Uprichard SL: The therapeutic potential of
RNA interference. FEBS Lett. 579:5996–6007. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen WH, Lecaros RL, Tseng YC, Huang L and
Hsu YC: Nanoparticle delivery of HIF1α siRNA combined with
photodynamic therapy as a potential treatment strategy for
head-and-neck cancer. Cancer Lett. 359:65–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Sasabe E, Tatemoto Y, Li D, Yamamoto T and
Osaki T: Mechanism of HIF-1alpha-dependent suppression of
hypoxia-induced apoptosis in squamous cell carcinoma cells. Cancer
Sci. 96:394–402. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Sasabe E, Zhou X, Li D, Oku N, Yamamoto T
and Osaki T: The involvement of hypoxia-inducible factor-1alpha in
the susceptibility to gamma-rays and chemotherapeutic drugs of oral
squamous cell carcinoma cells. Int J Cancer. 120:268–277. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Mimeault M and Batra SK: Hypoxia-inducing
factors as master regulators of stemness properties and altered
metabolism of cancer- and metastasis-initiating cells. J Cell Mol
Med. 17:30–54. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Jing S, Wang J, Liu Q, Cheng Y, Yang C,
Wang Y, Cao F, Wen B, Jiao W and Guo Y: Relationship between
hypoxia inducible factor-1α and esophageal squamous cell carcinoma:
A meta analysis. Zhonghua Bing Li Xue Za Zhi. 43:593–599. 2014.(In
Chinese). PubMed/NCBI
|
|
41
|
Xie J, Jin B, Li DW, Shen B, Cong N, Zhang
TZ and Dong P: ABCG2 regulated by MAPK pathways is associated with
cancer progression in laryngeal squamous cell carcinoma. Am J
Cancer Res. 4:698–709. 2014.PubMed/NCBI
|
|
42
|
Doyle LA, Yang W, Abruzzo LV, Krogmann T,
Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter
from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA.
95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Z, Liu F, Ren Q, Zhao Q, Ren H, Lu S,
Zhang L and Han Z: Suppression of ABCG2 inhibits cancer cell
proliferation. Int J Cancer. 126:841–851. 2010.PubMed/NCBI
|
|
44
|
Noguchi K, Katayama K and Sugimoto Y:
Human ABC transporter ABCG2/BCRP expression in chemoresistance:
Basic and clinical perspectives for molecular cancer therapeutics.
Pharmgenomics Pers Med. 5:53–64. 2014.
|
|
45
|
Natarajan K, Xie Y, Baer MR and Ross DD:
Role of breast cancer resistance protein (BCRP/ABCG2) in cancer
drug resistance. Biochem Pharmacol. 15:1084–1103. 2012. View Article : Google Scholar
|
|
46
|
Nakanishi T and Ross DD: Breast cancer
resistance protein (BCRP/ABCG2): Its role in multidrug resistance
and regulation of its gene expression. Chin J Cancer. 31:73–99.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Hynes RO: Integrins: Bidirectional,
allosteric signaling machines. Cell. 110:673–687. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Steglich A, Vehlow A, Eke I and Cordes N:
α integrin targeting for radiosensitization of three-dimensionally
grown human head and neck squamous cell carcinoma cells. Cancer
Lett. 357:542–548. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Hehlgans S, Haase M and Cordes N:
Signalling via integrins: Implications for cell survival and
anticancer strategies. Biochim Biophys Acta. 1775:163–180.
2007.PubMed/NCBI
|
|
50
|
Onodera Y, Nam JM and Sabe H:
Intracellular trafficking of integrins in cancer cells. Pharmacol
Ther. 140:1–9. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Desgrosellier JS and Cheresh DA: Integrins
in cancer: Biological implications and therapeutic opportunities.
Nat Rev Cancer. 10:9–22. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lukacs RU, Memarzadeh S, Wu H and Witte
ON: Bmi-1 is a crucial regulator of prostate stem cell self-renewal
and malignant transformation. Cell Stem Cell. 7:682–693. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Li Z, Wang Y, Yuan C, Zhu Y, Qiu J, Zhang
W, Qi B, Wu H, Ye J, Jiang H, et al: Oncogenic roles of Bmi1 and
its therapeutic inhibition by histone deacetylase inhibitor in
tongue cancer. Lab Invest. 94:1431–1445. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Mazumdar A, Henderson YC, El-Naggar AK,
Sen S and Clayman GL: Aurora kinase A inhibition and paclitaxel as
targeted combination therapy for head and neck squamous cell
carcinoma. Head Neck. 31:625–634. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Bischoff JR, Anderson L, Zhu Y, Mossie K,
Ng L, Souza B, Schryver B, Flanagan P, Clairvoyant F, Ginther C, et
al: A homologue of Drosophila aurora kinase is oncogenic and
amplified in human colorectal cancers. EMBO J. 17:3052–3065. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Goepfert TM, Adigun YE, Zhong L, Gay J,
Medina D and Brinkley WR: Centrosome amplification and
overexpression of aurora A are early events in rat mammary
carcinogenesis. Cancer Res. 62:4115–4122. 2002.PubMed/NCBI
|
|
57
|
Kovarikova V, Burkus J, Rehak P, Brzakova
A, Solc P and Baran V: Aurora kinase A is essential for correct
chromosome segregation in mouse zygote. Zygote. 15:326–337. 2016.
View Article : Google Scholar
|
|
58
|
Katsha A, Belkhiri A, Goff L and El-Rifai
W: Aurora kinase A in gastrointestinal cancers: Time to target. Mol
Cancer. 20:1062015. View Article : Google Scholar
|
|
59
|
Sun JM, Yang LN, Xu H, Chang B, Wang HY
and Yang G: Inhibition of Aurora A promotes chemosensitivity via
inducing cell cycle arrest and apoptosis in cervical cancer cells.
Am J Cancer Res. 5:1133–1145. 2015.PubMed/NCBI
|
|
60
|
Tanaka H, Nakashiro K, Iwamoto K, Tokuzen
N, Fujita Y, Shirakawa R, Oka R, Goda H and Hamakawa H: Targeting
Aurora kinase A suppresses the growth of human oral squamous cell
carcinoma cells in vitro and in vivo. Oral Oncol. 49:551–559. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Whitehead KA, Langer R and Anderson DG:
Knocking down barriers: Advances in siRNA delivery. Nat Rev Drug
Discov. 8:129–138. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: ClinicalTrials.gov Background. Available from.
https://clinicaltrials.gov/ct2/about-site/backgroundAccessed.
June 29–2015
|
|
63
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: APN401 in Treating Patients With Melanoma,
Kidney Cancer, Pancreatic Cancer, or Other Solid Tumors That Are
Metastatic or Cannot Be Removed By Surgery. Available from.
http://clinicaltrials.gov/show/NCT02166255Accessed.
June 29–2015
|
|
64
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: EphA2 Gene Targeting Using Neutral Liposomal
Small Interfering RNA Delivery. Available from. http://clinicaltrials.gov/show/NCT01591356Accessed.
June 29–2015
|
|
65
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: Safety Study of CALAA-01 to Treat Solid Tumor
Cancers. Available from. http://clinicaltrials.gov/show/NCT00689065Accessed.
June 29–2015.
|
|
66
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: Phase I-Escalating Dose Study of siG12D LODER
(Local Drug EluteR) in Patients With Locally Advanced
Adenocarcinoma of the Pancreas and a Single Dose Study of siG12D
LODER (Local Drug EluteR) in Patients With Non-operable
Adenocarcinoma of the Pancreas. Available from. http://clinicaltrials.gov/show/NCT01188785Accessed.
June 29–2015.
|
|
67
|
U.S. National Institutes of Health, .
ClinicalTrials.gov: A Phase II Study of siG12D LODER in Combination
With Chemotherapy in Patients With Unresectable Locally Advanced
Pancreatic Cancer. Available from. http://clinicaltrials.gov/show/NCT01676259Accessed.
June 29–2015
|
